Name : Human CLEC12A/MICL/CLL-1 Protein
Product Source :
Recombinant Human CLEC12A/MICL/CLL-1 Protein is expressed from HEK293 with His tag at the N-Terminus. It contains His65-Ala265.[Accession | Q5QGZ9-2]
Molecular Weight :
The protein has a predicted MW of 24.6 kDa. Due to glycosylation, the protein migrates to 38-55 kDa based on Tris-Bis PAGE result.
Endotoxin Level :
Less than 1EU per μg by the LAL method.
Purity :
> 95% as determined by Tris-Bis PAGE
Formulation :
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution :
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage and Stability :
-20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3-6 months after reconstitution. 2-8°C for 2-7 days after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Product Concentration :
Tris-Bis PAGE Human CLEC12A on Tris-Bis PAGE under reduced condition. The purity is greater than 95%. ELISA Data Immobilized Human CLEC12A at 0.5μg (100μl/Well) on the plate. Dose response curve for Anti-CLEC12A Antibody, hFc Tag with the EC50 of 3.7ng/ml determined by ELISA.
Background :
CLEC12A has recently been identified as an antigen, expressed on leukemic stem cells and leukemic blasts. Given the fact that this expression profile seems stable throughout diagnosis, treatment and relapse on leukemic blasts and leukemic stem cells, CLEC12A can be considered a highly potent and reliable marker for the detection of measurable residual disease and therefore applicable for risk stratification and prognostication in AML.
Synonyms :
MICL; CLL-1; CLEC12A; CLL1; DCAL2; DCAL-2; CD371; CD303; CLECSF11; CLECSF7; DLEC; HECL; PRO34150; DCAL-2
References & Citations :
(1)Bill M, Aggerholm A, Kjeldsen E, Roug AS, Hokland P, Nederby L. Revisiting CLEC12A as leukaemic stem cell marker in AML: highlighting the necessity of precision diagnostics in patients eligible for targeted therapy. Br J Haematol. 2019 Mar;184(5):769-781. doi: 10.1111/bjh.15711. Epub 2018 Dec 5. PMID: 30520015.
Related category websites: https://www.medchemexpress.com/recombinant-proteins.html
Popular product recommendations:
TPM2 ProteinSource
IL-10 Proteinweb
Popular categories:
Osteoprotegerin
IL-8/CXCL8